Rehabiliation Using HUBER 360 to Reduce the Risk of Falls

NCT ID: NCT04687293

Last Updated: 2023-05-12

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: NA
• Total Enrollment: 32 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2020-12-09
• Study Completion Date: 2022-11-02

Brief Summary

Aim: The aim of the present study was to analyse the effects of training performed on a rotating, motorised platform (the Huber/SpineForce device from LPG Systems, Valence, France) intended to reduce the risk of falls.

Subjects: any patient 1) benefiting from a physiotherapy rehabilitation program at the CHU Liège, CNRF, Belgium; 2) presenting a pathological situation justifying functional rehabilitation with HUBER 360®; 3) presenting any pathology not constituting an exclusion criterion; 4) giving informed consent to research will be include in this 8-week interventional trial.

Design: randomized open-label trial. Patients will be randomized into the intervention group (HUBER trainig, 45 minutes of training, twice a week during 8 weeks) or in the control group (standard care).

Outcomes: the effect of the training will be measured on the Time-Up-and-Go test, on the Short-Physical performance battery test and on quality of life.

Conditions

Rehabilitation; Exercise Therapy; Treatment Outcome; Quality of Life; Fall

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

HUBER

HUBER is an isometric strengthening device. It consists of an oval motorized platform, which performs rotating, oscillatory movements with a controlled amplitude and speed.

Intervention will consist of 2 sessions of HUBER per week. Each session lasts approximatively 30 minutes. The intervention is 8 weeks long.

Group Type: EXPERIMENTAL

HUBER (LPG Systems, France)

Intervention Type: DEVICE

The HUBER® device consists of an oval motorized platform, which performs rotating, oscillatory movements with a controlled amplitude and speed. It also comprises, two large handles with force sensors, mounted on a movable column. Its originality is based on its capacity to capture simultaneously the subjects' balance, core stability, core strength and total body strength; and adapt the training accordingly. Indeed, the platform interferes with the balance of the patient who must continually adjust his/her posture by exerting isometric pushing and pulling efforts with the arms. As a result, the device provides postural and muscle adaptation with visual feedback. Due to the constant adaptation of the device, it is thought to enhance muscular strength and improve neuromuscular coordination simultaneously.

Control

The control group will not received any intervention except usual care.

Group Type: NO_INTERVENTION

No interventions assigned to this group

Interventions

HUBER (LPG Systems, France)

The HUBER® device consists of an oval motorized platform, which performs rotating, oscillatory movements with a controlled amplitude and speed. It also comprises, two large handles with force sensors, mounted on a movable column. Its originality is based on its capacity to capture simultaneously the subjects' balance, core stability, core strength and total body strength; and adapt the training accordingly. Indeed, the platform interferes with the balance of the patient who must continually adjust his/her posture by exerting isometric pushing and pulling efforts with the arms. As a result, the device provides postural and muscle adaptation with visual feedback. Due to the constant adaptation of the device, it is thought to enhance muscular strength and improve neuromuscular coordination simultaneously.

Intervention Type: DEVICE

Eligibility Criteria

Inclusion Criteria

• Patient benefiting from a physiotherapy rehabilitation program at the CHU Liège, CNRF
• Patient presenting a pathological situation justifying functional rehabilitation with HUBER 360®
• Patient presenting any pathology not constituting an exclusion criterion
• Patient giving informed consent to research.

Exclusion Criteria

• Cardiac or respiratory or neurological or rheumatological disease incompatible with physical activity ;
• Joint inflammation;
• Rheumatic disease in acute phase;
• Recent trauma, infection of the musculoskeletal system;
• Fever;
• Venous thrombosis ;
• Discopathy in acute phase;
• Neuropsychological problems that do not allow to integrate the instructions or other serious psychological problems;
• Cardiovascular diseases and any progressive, chronic, counter-indicative disease;
• Large anatomical deformities.

• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

University of Liege

OTHER

Sponsor Role: lead

Responsible Party

Charlotte Beaudart

Principal investigator

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

Jean-François Kaux, MD PhD

Role: STUDY_DIRECTOR

Centre Hospitalier Universitaire de Liege

Locations

CHU Liège, CNRF

Tinlot, Liège, Belgium

Countries

Belgium

Other Identifiers

HUBER_CNRF01

Identifier Type: -

Identifier Source: org_study_id